
Letrozole 2.5mg Tablets
Letrozole 2.5mg Tablets are Anti Cancer drugs. The active ingredient in these tablets is Letrozole, which is a nonsteroidal aromatase inhibitor. They are odorless and practically insoluble in water. Femara is the universal name of these tablets by which they are available in pharmacies.
Letrozole 2.5mg Tablets prevent breast cancer from coming back. They also decrease the amount of estrogen hormone that the body makes and also helps to reverse or slow the growth of cancer. Prevention of the production of unnecessary estrogen inhibits the development of breast cancer.
If you become pregnant or there are even minor chances of getting pregnant, discuss it right away with your doctor.
1. What is Femara?
Femara is an anti-cancer medicine containing letrozole 2.5 mg, a nonsteroidal aromatase inhibitor. It works by reducing estrogen production in the body and is primarily used in the hormonal treatment of certain types of breast cancer.
2. What is Femara used for?
Femara (letrozole) is used for the treatment of certain hormone receptor-positive breast cancers, particularly in postmenopausal women. It may be used as adjuvant treatment for early breast cancer or for advanced or metastatic breast cancer according to the applicable treatment protocol and prescribing information.
3. How does Femara work?
Femara works by inhibiting the aromatase enzyme, which is responsible for converting certain hormones into estrogen. Lowering estrogen levels can reduce hormonal stimulation of estrogen-dependent breast cancer cells.
4. What strength of Femara is available from Lotus International?
Lotus International lists Letrozole 2.5 mg Tablets under the Femara brand. Product availability, packaging and supply conditions may vary depending on the destination market and applicable pharmaceutical regulations.
5. What are the possible side effects of Femara?
Possible side effects of letrozole may include hot flashes, joint or muscle pain, fatigue, dizziness, headache, nausea and increased cholesterol levels. Letrozole may also affect bone mineral density, so appropriate medical monitoring may be recommended during treatment.